Skip to: Content
Skip to: Site Navigation
Skip to: Search

September 5, 2008 11:53:06 AM CDT

Learn about Newser Points »

« Back to the grid | Next story »

Roche Makes Genentech Takeover Bid

Posted Jul 21, 08 6:55 AM CDT in Science & Health,  Business 

(Newser) – Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug development has been lagging, stepping up investment in the more productive biotech sector.

But the move potentially puts at risk the independent research that the biotech firm—and Roche—has thrived on. Under the loose reins of Roche’s arms-length management, Genentech has produced an array of cancer drugs, including Avastin, Rituxan, and Herceptin, that generate more than $1 billion a year in sales; in all, Genentech-developed drugs contributed nearly a third of Roche's 2007 sales last year.

Source Wall Street Journal

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon

Related Newser Stories

  • Anheuser-Busch: The Deal That Sleeps With the Fishes

    Jul 17, 08 11:40 AM CDT
    Anheuser-Busch: The Deal That Sleeps With the Fishes Anyone mourning the takeover of Anheuser Busch by Belgium's InBev might want to know that the real turning point in that battle occurred more than a decade ago. On a fishing trip. In Mexico. The last real chance to outmaneuver InBev was lost when the US brewer failed to get a controlling stake in Mexico’s Grupo Modelo, writes David Kesmodel in the Wall Street Journal. And chances for that, say industry sources, vanished when former A-B CEO August Busch III decided to take a call instead of landing a humongous marlin. More »

  • Cancer Drug Sales Push Genentech Profits Up 12%

    Apr 11, 08 8:28 AM CDT
    Cancer Drug Sales Push Genentech Profits Up 12% Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock edged up 0.3% in after-hours trading. More »

  • Tumbling Yahoo Now a Target?

    Jan 11, 08 9:51 PM CST
    Tumbling Yahoo Now a Target? Yahoo's falling core value threatens the company's future and is ringing alarm bells for investors, the New York Times’ Saul Hansell warned in his "Bits" blog. The central business of Yahoo.com, excluding subsidiary holdings, is worth less than half of its current share price, and a paltry 7% of Google’s $200 billion market value, according to one analyst quoted by Hansell. More »

  • Biotech Giant Slashes Jobs

    Aug 16, 07 1:34 AM CDT
    Biotech Giant Slashes Jobs Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune to the problems that plague traditional drug companies, the Wall Street Journal reports. More »

Franz B. Humer, chairman of the board and CEO of Swiss pharmaceutical company Roche Holding.   (AP Photo/Keystone, Georgios Kefalas)
A Roche worker supervises the package of the Tamiflu, the drug that combats the effects of bird flu in humans.   (AP Photo/Keystone, Roche)
Franz B. Humer, chairman of the board and CEO of Swiss pharmaceutical company Roche Holding AG.   (AP Photo/Keystone, Georgios Kefalas)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (1 of 2)

Tags

mergers and acquisitions  • takeover  • Genentech  • Roche Holding


Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular


Other Business Stories

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »